Evidence map›Paper›PMID 27822414›Full record

ArticleAmerican journal of cancer research2016

Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Marta Llauradó Fernández, Gabriel E DiMattia, Amy Dawson, Sylvia Bamford, Shawn Anderson, Bryan T Hennessy, Michael S Anglesio, Trevor G Shepherd, Clara Salamanca, Josh Hoenisch and 3 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Molecular changes driving low-grade serous ovarian cancer and implications for treatment.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas.Cold Spring Harbor perspectives in medicine · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Marta Llauradó FernándezDepartment of Obstetrics & Gynaecology, University of British Columbia Vancouver, British Columbia, Canada.
Gabriel E DiMattiaTranslational Ovarian Cancer Research Program, London Regional Cancer ProgramLondon, Ontario, Canada; Department of Biochemistry, University of Western OntarioLondon, Ontario, Canada; Department of Obstetrics & Gynecology, University of Western OntarioLondon, Ontario, Canada; Department of Oncology, University of Western OntarioLondon, Ontario, Canada.
Amy DawsonDepartment of Reproductive and Developmental Sciences, University of British Columbia Vancouver, British Columbia, Canada.
Sylvia BamfordDepartment of Obstetrics & Gynaecology, University of British Columbia Vancouver, British Columbia, Canada.
Shawn AndersonDepartment of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia Vancouver, British Columbia, Canada.
Bryan T HennessyBeaumont Hospital and Royal College of Surgeons of Ireland Dublin, Ireland.
Michael S AnglesioDepartment of Obstetrics & Gynaecology, University of British ColumbiaVancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British ColumbiaVancouver, British Columbia, Canada.
Trevor G ShepherdTranslational Ovarian Cancer Research Program, London Regional Cancer ProgramLondon, Ontario, Canada; Department of Obstetrics & Gynecology, University of Western OntarioLondon, Ontario, Canada; Department of Oncology, University of Western OntarioLondon, Ontario, Canada; Department of Anatomy and Cell Biology, University of Western OntarioLondon, Ontario, Canada.
Clara SalamancaDepartment of Pathology and Laboratory Medicine, University of British Columbia Vancouver, British Columbia, Canada.
Josh HoenischDepartment of Obstetrics & Gynaecology, University of British Columbia Vancouver, British Columbia, Canada.
Anna TinkerDepartment of Medical Oncology, BC Cancer Agency Vancouver, British Columbia, Canada.
David G HuntsmanDepartment of Obstetrics & Gynaecology, University of British ColumbiaVancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British ColumbiaVancouver, British Columbia, Canada; Department of Molecular Oncology, BC Cancer AgencyVancouver, British Columbia, Canada.
Mark S CareyDepartment of Obstetrics & Gynaecology, University of British ColumbiaVancouver, British Columbia, Canada; Department of Surgical Oncology, BC Cancer AgencyVancouver, British Columbia, Canada.
University of British Columbia · CAWestern University · CABC Cancer Agency · CABeaumont Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry mutations in

Indexed as

cell line modelscopy-number alterationsERK1/2 phosphorylationgene mutationsLow-grade serous ovarian cancerMAPK signallingMEK inhibitors

Identifiers

PMID27822414
PMCPMC5088288
OpenAlexW2567323329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.